Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. Co. is engaged in developing a pipeline of immunotherapies for the treatment of cancer. Co. provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. Co.'s lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). It is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). We show 3 historical shares outstanding datapoints in our ELTX shares outstanding history coverage, used to compute ELTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ELTX market cap history over the course of time is important for investors
interested in comparing ELTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ELTX versus a peer is one thing; comparing
ELTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ELTX can fluctuate over the course of history.
With this page we aim to empower investors researching ELTX by allowing them to research the ELTX market cap history. |
Free ELTX Email Alerts:
Video: The Importance of Market Cap
